Skip to main content

Table 3 Breakdown of costs considering/not considering the increased risk due to medical history

From: Cost-Effectiveness Analysis of Linagliptin in Japan Based on Results from the Asian Subpopulation in the CARMELINA® Trial

  Cost (yen)
SoC Linagliptin plus SoC
Medical history considered
 Drug costa NA 567,107
 CV death 1,129,847 938,361
 Renal failure 11,409,876 11,238,312
 Albuminuria progression 0 0
 Hospitalisation for heart failure 1,655,472 966,711
 Hospitalisation for unstable angina 29,807 30,254
 Nonfatal stroke 331,431 259,619
 Nonfatal myocardial infarction 181,314 192,064
Medical history not considered
 Drug costa NA 815,879
 CV death 469,480 349,250
 Renal failure 12,638,256 8,316,517
 Albuminuria progression 0 0
 Hospitalisation for heart failure 556,624 284,082
 Hospitalisation for unstable angina 48,600 38,007
 Nonfatal stroke 310,023 196,019
 Nonfatal myocardial infarction 281,574 257,558
  1. CV cardiovascular, NA not applicable, SoC standard of care
  2. a2019 linagliptin prices were used